Overview

Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To monitor the safety of Metalyse® in clinical practice in patients with acute myocardial infarction over a period of 6 years as required by Korean authorities, with the following observations: 1. Unexpected adverse drug reactions 2. Frequency and nature of adverse events (AEs) 3. Factors on the safety and efficacy profile of the Metalyse® Injection. Efficacy of Metalyse® was also assessed.
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Tenecteplase
Tissue Plasminogen Activator